Melatonina
Anno: 2009
-
Riferimento:Postepy Hig Med Dosw (Online). 2009 Sep 15;63:425-34.Azione della melatonina:MT1 melatonin receptors benefits the efficacy of melatonin treatment.Target:MT1 (Mel1a) and MT2 (Mel1b) receptors.
-
Riferimento:Cancer Lett. 2009 Aug 18;281(1):1-7.Azione della melatonina:In breast cancer risk, melatonin may also block the estrogen receptor ERalpha and impact the enzyme aromatase, which produces estradiol.Target:Estrogen receptor Eralpha Enzyme aromatase.
-
Riferimento:Ann N Y Acad Sci. 2009 Aug;1171:345-9.Azione della melatonina:Stimulate reactive oxygen species (ROS).Target:EBV inhibits melatonin anti-apoptotic effects.
-
Riferimento:Br J Cancer. 2009 Nov 3;101(9):1613-9.Azione della melatonina:Melatonin(1nM)inhibits aromatase activity and expression by regulating the gene expression of specific aromatase promote region pI.4, and inhibit COX-2 and COX-1 mRNA expression.Target:COX-2/COX-1 mRNA expression.
-
Riferimento:J Pineal Res. 2009 Jan;46(1):115-6.Azione della melatonina:No abstract available.Target:No abstract available.
-
Riferimento:Cancer Causes Control. 2009 Nov;20(9):1753-6.Azione della melatonina:Blind women withNPL(no perception of light)appear to have a lower risk of breast cancer, compared to blind women with LP. Mechanisms influenced by melatonin or circadian synchronization.Target:Blindness.
-
Riferimento:Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.Azione della melatonina:N(4-chlorobenzoyl)melatonin as a specific AKR1C3 inhibitor validate its role in the proliferation of breast cancer cells.Target:Aldo-keto reductase (AKR) 1C3
-
Titolo: sis in B-lymphoma cellsRiferimento:Ann N Y Acad Sci. 2009 Aug;1171:345-9.Azione della melatonina:Melatonin is considered a promising antitumor agent, promoting apoptosis in tumor cells and contrasting it in normal cells.Target:Apoptosis modulator.
-
Riferimento:J Pineal Res. 2009 May;46(4):422-32.Azione della melatonina:Expression of MT1 and coexpression of MT1/ nestin in invading tumor cells in more advanced tumors suggest an important role for GPCR in pathogenesis of breast cancer.Target:G-protein-coupled receptor (GPCR).
-
Riferimento:Free Radic Biol Med. 2009 Jan 15;46(2):253-62.Azione della melatonina:NQO2 is a newly discovered binding site (MT3) of melatonin, indicating that it could be a novel target for prevention of breast cancer initiation.Target:Quinone oxidoreductase 2 (NQO2).